Bio-Techne financials
$72.38−0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.2M | $311.4M | $295.9M | $286.6M | $317.0M | $316.2M | $297.0M | $289.5M | $306.1M | $303.4M | $272.6M | $276.9M |
| Gross profit | $211.4M | $208.3M | $191.3M | $188.1M | $198.8M | $214.6M | $193.9M | $183.0M | $203.3M | $204.6M | $176.6M | $185.2M |
| Gross margin | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% | 66.4% | 67.4% | 64.8% | 66.9% |
| Operating income | $74.3M | $75.5M | $54.5M | $47.7M | -$23.9M | $38.7M | $47.4M | $40.0M | $45.8M | $67.0M | $38.0M | $55.9M |
| Net income | $54.6M | $51.0M | $38.0M | $38.2M | -$17.7M | $22.6M | $34.9M | $33.6M | $40.6M | $49.1M | $27.5M | $51.0M |
| Net margin | 17.0% | 16.4% | 12.8% | 13.3% | −5.6% | 7.1% | 11.7% | 11.6% | 13.3% | 16.2% | 10.1% | 18.4% |
| Diluted EPS | $0.35 | $0.32 | $0.24 | $0.24 | $-0.11 | $0.14 | $0.22 | $0.21 | $0.25 | $0.31 | $0.17 | $0.31 |
| EBITDA | $98.4M | $99.7M | $79.2M | $72.0M | $3.3M | $66.3M | $74.5M | $68.1M | $73.9M | $94.3M | $65.8M | $84.4M |
| Operating cash flow | $95.4M | $86.7M | $82.4M | $27.6M | $98.2M | $41.1M | $84.3M | $63.9M | $75.5M | $81.0M | $83.1M | $59.4M |
| Free cash flow | $86.9M | $77.6M | $76.5M | $22.2M | $93.3M | $31.0M | $77.5M | $54.7M | $57.5M | $64.5M | $68.3M | $45.8M |
| Diluted shares | 157.3M | 157.4M | 157.0M | 156.4M | 158.2M | 158.9M | 160.6M | 161.1M | 160.6M | 160.5M | 160.1M | 161.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $264.7M | $209.8M | $172.9M | $145.0M | $162.2M | $140.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $200.0M | $200.0M | $260.0M | $300.0M | $346.0M | $330.0M |
| Total assets | $2.59B | $2.55B | $2.52B | $2.53B | $2.56B | $2.64B |
| Total liabilities | $478.5M | $465.3M | $511.7M | $560.3M | $639.1M | $626.2M |
| Shareholders' equity | $2.11B | $2.09B | $2.01B | $1.97B | $1.92B | $2.02B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology